Liraglutide, a glucagon-like peptide-1 agonist, has been shown to have beneficial effects on fecal output in short bowel syndrome (SBS) by small human studies. Here, GCG is linked to macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss.